Neuralstem uses its patented technology to produce neural stem cells of the human brain and spinal cord. Neuralstem is in an FDA-approved phase I safety clinical trial for Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA; has submitted an IND application for a phase I safety trial in chronic spinal cord injury; and has received FDA approval to conduct a phase Ib safety trial evaluating NSI-189 for the treatment of major depressive disorder (MDD). For more information visit the company’s Web site at: www.neuralstem.com.

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.

Let us hear your thoughts below: